Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov 14;20(42):15532-8.
doi: 10.3748/wjg.v20.i42.15532.

Liver transplantation and non-alcoholic fatty liver disease

Petros Zezos  1 , Eberhard L Renner  1
Affiliations
Review

Liver transplantation and non-alcoholic fatty liver disease

Petros Zezos et al. World J Gastroenterol. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an important health problem worldwide. NAFLD encompasses a histological spectrum ranging from bland liver steatosis to severe steatohepatitis (nonalcoholic steatohepatitis, NASH) with the potential of progressing to cirrhosis and its associated morbidity and mortality. NAFLD is thought to be the hepatic manifestation of insulin resistance (or the metabolic syndrome); its prevalence is increasing worldwide in parallel with the obesity epidemic. In many developed countries, NAFLD is the most common cause of liver disease and NASH related cirrhosis is currently the third most common indication for liver transplantation. NASH related cirrhosis is anticipated to become the leading indication for liver transplantation within the next one or two decades. In this review, we discuss how liver transplantation is affected by NAFLD, specifically the following: (1) the increasing need for liver transplantation due to NASH; (2) the impact of the increasing prevalence of NAFLD in the general population on the quality of deceased and live donor livers available for transplantation; (3) the long term graft and patient outcomes after liver transplantation for NASH, and finally; and (4) the de novo occurrence of NAFLD/NASH after liver transplantation and its impact on graft and patient outcomes.

Keywords: Hepatic steatosis; Insulin resistance; Liver cirrhosis; Liver transplantation; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity; Steatohepatitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Natural history of the nonalcoholic fatty liver disease. NAFL: Nonalcoholic fatty liver; NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; NAFLD: Nonalcoholic fatty liver disease.
Figure 2
Figure 2
Impact of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis on liver transplantation. LT: Liver transplantation; NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; NAFLD: Nonalcoholic fatty liver disease.
See this image and copyright information in PMC

References

    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. - PubMed
    1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339–350. - PubMed
    1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. - PubMed
    1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–1350. - PubMed
    1. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–238. - PubMed

MeSH terms